The DOI matches its Crossref record; 238 of the 238 references it cites were found in a registry or an index.
Critical Reanalysis of the Mechanisms Underlying the Cardiorenal Benefits of SGLT2 Inhibitors and Reaffirmation of the Nutrient Deprivation Signaling/Autophagy Hypothesis
Open accessAbstract
SGLT2 (sodium-glucose cotransporter 2) inhibitors produce a distinctive pattern of benefits on the evolution and progression of cardiomyopathy and nephropathy, which is characterized by a reduction in oxidative and endoplasmic reticulum stress, restoration of mitochondrial health and enhanced mitochondrial biogenesis, a decrease in proinflammatory and profibrotic pathways, and preservation of cellular and organ integrity and viability. A substantial body of evidence indicates that this characteristic pattern of responses can be explained by the action of SGLT2 inhibitors to promote cellular housekeeping by enhancing autophagic flux, an effect that may be related to the action of these drugs to produce simultaneous upregulation of nutrient deprivation signaling and downregulation of nutrient surplus signaling, as manifested by an increase in the expression and activity of AMPK (adenosine monophosphate–activated protein kinase), SIRT1 (sirtuin 1), SIRT3 (sirtuin 3), SIRT6 (sirtuin 6), and PGC1-α (peroxisome proliferator–activated receptor γ coactivator 1-α) and decreased activation of mTOR (mammalian target of rapamycin). The distinctive pattern of cardioprotective and renoprotective effects of SGLT2 inhibitors is abolished by specific inhibition or knockdown of autophagy, AMPK, and sirtuins. In the clinical setting, the pattern of differentially increased proteins identified in proteomics analyses of blood collected in randomized trials is consistent with these findings. Clinical studies have also shown that SGLT2 inhibitors promote gluconeogenesis, ketogenesis, and erythrocytosis and reduce uricemia, the hallmarks of nutrient deprivation signaling and the principal statistical mediators of the ability of SGLT2 inhibitors to reduce the risk of heart failure and serious renal events. The action of SGLT2 inhibitors to augment autophagic flux is seen in isolated cells and tissues that do not express SGLT2 and are not exposed to changes in environmental glucose or ketones and may be related to an ability of these drugs to bind directly to sirtuins or mTOR. Changes in renal or cardiovascular physiology or metabolism cannot explain the benefits of SGLT2 inhibitors either experimentally or clinically. The direct molecular effects of SGLT2 inhibitors in isolated cells are consistent with the concept that SGLT2 acts as a nutrient surplus sensor, and thus, its inhibition causes enhanced nutrient deprivation signaling and its attendant cytoprotective effects, which can be abolished by specific inhibition or knockdown of AMPK, sirtuins, and autophagic flux.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–238 of 238
Luo, J., Sun, P., Wang, Y., Chen, Y., Niu, Y., Ding, Y., Xu, N., Zhang, Y., & Xie, W. (2021) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2021.174304 · Cited by 38
Sympathetic Denervation Ameliorates Renal Fibrosis via Inhibition of Cellular Senescence
Li, Q., Deng, Y., Liu, L., Zhang, C., Cai, Y., Zhang, T., Han, M., & Xu, G. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2021.823935 · Cited by 37
SIRT3 Deficiency Sensitizes Angiotensin-II-Induced Renal Fibrosis
Feng, X., Su, H., He, X., Chen, J., & Zeng, H. (2020) · Cells · doi:10.3390/cells9112510 · Cited by 36
Huang, Y., Zhang, J., Xu, D., Yu, P., Jin, Y., & Zhang, L. (2021) · Molecular Medicine Reports · doi:10.3892/mmr.2021.12006 · Cited by 36
Fukushima, K., Kitamura, S., Tsuji, K., Sang, Y., & Wada, J. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21114054 · Cited by 35
He, L., Li, Y., Zhang, D., Song, H., Xu, D., & Song, Z. (2022) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2022.05.022 · Cited by 35
Kim, J. H., Ko, H. Y., Wang, H. J., Lee, H., Yun, M., & Kang, E. S. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13905 · Cited by 34
Mohamed, H. E., Asker, M. E.-S., Keshawy, M. M., Hasan, R. A., & Mahmoud, Y. K. (2020) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-020-03686-x · Cited by 34
Lysosome Depletion-Triggered Autophagy Impairment in Progressive Kidney Injury
Chen, X., Li, Z., Yang, C., Tang, J., Lan, H.-Y., & Liu, H. (2021) · Kidney Diseases · doi:10.1159/000515035 · Cited by 34
Xu, L., Xu, C., Liu, X., Li, X., Li, T., Yu, X., Xue, M., Yang, J., Kosmas, C. E., Moris, D., et al. (2021) · Frontiers in Physiology · doi:10.3389/fphys.2021.745058 · Cited by 34
Hare, G. M. T., Zhang, Y., Chin, K., Thai, K., Jacobs, E., Cazorla‐Bak, M. P., Nghiem, L., Wilson, D. F., Vinogradov, S. A., Connelly, K. A., et al. (2021) · Physiological Reports · doi:10.14814/phy2.14890 · Cited by 33
Wang, S., Fu, C., Wang, H., Shi, Y., Xu, X.-Q., Chen, J., Song, X., Sun, K., Wang, J., Fan, X., et al. (2007) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm.2007.189 · Cited by 32
Mikami, D., Kobayashi, M., Uwada, J., Yazawa, T., Kamiyama, K., Nishimori, K., Nishikawa, Y., Morikawa, Y., Yokoi, S., Takahashi, N., et al. (2019) · Life Sciences · doi:10.1016/j.lfs.2019.03.008 · Cited by 32
McCallum, W. I., Tighiouart, H., Ku, E., Salem, D. N., & Sarnak, M. J. (2019) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2019.05.010 · Cited by 32
Wolf, P. S., Fellinger, P., Pfleger, L., Beiglböck, H., Krumpolec, P., Barbieri, C., Gastaldelli, A., Harreiter, J., Metz, M., Scherer, T., et al. (2020) · Diabetes Care · doi:10.2337/dc20-1983 · Cited by 32
Scholtes, R. A., Muskiet, M. H. A., van Baar, M. J. B., Hesp, A. C., Greasley, P. J., Hammarstedt, A., Karlsson, C., Hallow, K. M., Danser, A. H. J., Heerspink, H. J. L., et al. (2022) · Kidney International Reports · doi:10.1016/j.ekir.2022.02.023 · Cited by 31
Huang, D. Y., Gao, H., Boini, K. M., Oßwald, H., Nürnberg, B., & Lang, F. J. W. (2010) · Pflügers Archiv - European Journal of Physiology · doi:10.1007/s00424-010-0803-7 · Cited by 30
Zheng, H., Fu, Y., Huang, Y., Zheng, X., Yu, W., & Wang, W. (2017) · Molecular Medicine Reports · doi:10.3892/mmr.2017.7032 · Cited by 30
Renal sympathetic nerve activation via α2-adrenergic receptors in chronic kidney disease progression
Jang, H., Kim, J., & Padanilam, B. J. (2019) · Kidney Research and Clinical Practice · doi:10.23876/j.krcp.18.0143 · Cited by 29
Guo, X., Yan, F., Li, J., Zhang, C., Su, H., & Bu, P. (2020) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000000877 · Cited by 29
Herring, R. A., Shojaee‐Moradie, F., Stevenage, M., Parsons, I., Jackson, N., Mendis, J. R., Middleton, B., Umpleby, A. M., Fielding, B. A., Davies, M. J., et al. (2022) · Diabetes Care · doi:10.2337/dc21-2043 · Cited by 29
Fukuta, H., Goto, T., Wakami, K., Kamiya, T., & Ohte, N. (2020) · Heart Failure Reviews · doi:10.1007/s10741-020-09974-4 · Cited by 28
He, L., Ma, S., Zuo, Q., Zhang, G., Wang, Z., Zhang, T., Zhai, J., & Guo, Y. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.856386 · Cited by 28
Clinical impact of myocardial mTORC1 activation in nonischemic dilated cardiomyopathy
Yano, T., Shimoshige, S., Miki, T., Tanno, M., Mochizuki, A., Fujito, T., Yuda, S., Muranaka, A., Ogasawara, M., Hashimoto, A., et al. (2015) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2015.12.022 · Cited by 27
da Silva, C. A., Monteiro, M. L. G. D. R., Araújo, L. S., Urzedo, M. G., Rocha, L. B., dos Reis, M. A., & Machado, J. R. (2020) · PLoS ONE · doi:10.1371/journal.pone.0241745 · Cited by 27
Cardioprotective effects of short-term empagliflozin treatment in db/db mice
Radlinger, B., Hornsteiner, F., Folie, S., Salvenmoser, W., Haubner, B. J., Schuetz, T., Haas, S., Ress, C., Adolph, T. E., Salzmann, K., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-76698-8 · Cited by 27
AMPK mediates regulation of glomerular volume and podocyte survival
Banu, K., Lin, Q., Basgen, J. M., Planoutene, M., Wei, C., Reghuvaran, A. C., Tian, X., Shi, H., Garzon, F., Garzia, A., et al. (2021) · JCI Insight · doi:10.1172/jci.insight.150004 · Cited by 25
3-Hydroxybutyrate Ameliorates the Progression of Diabetic Nephropathy
Jung, J., Park, W. Y., Kim, Y. J., Kim, M. K., Choe, M., Jin, K., Seo, J. H., & Ha, E. (2022) · Antioxidants · doi:10.3390/antiox11020381 · Cited by 22
Hasegawa, K. (2019) · Clinical and Experimental Nephrology · doi:10.1007/s10157-019-01719-4 · Cited by 19
Ipragliflozin-induced improvement of liver steatosis in obese mice may involve sirtuin signaling
Suga, T., Sato, K., Ohyama, T., Matsui, S., Kobayashi, T., Tojima, H., Horiguchi, N., Yamazaki, Y., Kakizaki, S., Nishikido, A., et al. (2020) · World Journal of Hepatology · doi:10.4254/wjh.v12.i7.350 · Cited by 18
Zhai, R., Liu, Y., Tong, J., Yu, Y., Yang, L., Gu, Y., & Niu, J. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.826792 · Cited by 18
Tokarska-Schlattner, M., Kay, L., Perret, P., Isola, R., Attia, S., Lamarche, F., Tellier, C., Cottet‐Rousselle, C., Uneisi, A., Hininger‐Favier, I., et al. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.731015 · Cited by 15
Sirtuin Activation: A Role for Plasma Membrane in the Cell Growth Puzzle
Crane, F. L., Navas, P., Löw, H., SUN, I. L., & de Cabo, R. (2012) · The Journals of Gerontology Series A · doi:10.1093/gerona/gls184 · Cited by 14
Chan, L. K. Y., Wang, Y., Ng, E. K., & Leung, P. S. (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13151 · Cited by 14
Nam, D. H., Kim, E., Benham, A. L., Park, H.-K., Soibam, B., Taffet, G. E., Kaelber, J. T., Suh, J. H., Taegtmeyer, H., Entman, M. L., et al. (2018) · The FASEB Journal · doi:10.1096/fj.201800602r · Cited by 12
Osaka, N., Mori, Y., Terasaki, M., Hiromura, M., Saito, T., Yashima, H., Shiraga, Y., Kawakami, R., Ohara, M., Fukui, T., et al. (2022) · Journal of International Medical Research · doi:10.1177/03000605221097490 · Cited by 12
Li, J., He, Q., Wu, W., Li, Q., Huang, R., Pan, X., & Lai, W. (2016) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2016.3669 · Cited by 9
SGLT2 Inhibition by Dapagliflozin Attenuates Diabetic Ketoacidosis in Mice with Type-1 Diabetes
Chen, H., Birnbaum, Y., Ye, R., Yang, H., Bajaj, M., & Ye, Y. (2021) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-021-07243-6 · Cited by 9
Cited by
Cardiovascular-kidney-metabolic health: a presidential advisory from the American Heart Association
Ndumele, C. E., Rangaswami, J., Chow, S. L., Neeland, I. J., Tuttle, K. R., Khan, S. S., Coresh, J., Mathew, R. O., Baker-Smith, C. M., Carnethon, M. R., et al. (2023) · Circulation · doi:10.1161/cir.0000000000001184 · Cited by 2,208
Heart Failure With Preserved Ejection Fraction
Borlaug, B. A., Sharma, K., Shah, S. J., & Ho, J. E. (2023) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2023.01.049 · Cited by 742
Cardiovascular risk in diabetes mellitus: Epidemiology, assessment and prevention
Wong, N. D., & Sattar, N. (2023) · Nature Reviews Cardiology · doi:10.1038/s41569-023-00877-z · Cited by 495
Neuen, B. L., Fletcher, R. A., Heath, L., Perkovic, A., Vaduganathan, M., Badve, S. V., Tuttle, K. R., Pratley, R., Gerstein, H. C., Perkovic, V., et al. (2024) · Circulation · doi:10.1161/circulationaha.124.071689 · Cited by 168
Obesity accelerates cardiovascular ageing
Ruperez, C., Madeo, F., de Cabo, R., Kroemer, G., & Abdellatif, M. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf216 · Cited by 73
Metadata
- Authors
- Packer, M.
- Venue
- Circulation
- Published
- 2022-11
- Volume
- 146
- Issue
- 18
- Pages
- 1383-1405
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- OpenAlex
- W4307886872
- Cited by
- 425
- References
- 238
- FWCI
- 52.70
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.